JPRN-UMIN000030457
Completed
Phase 2
Phase II trial of early secondary treatment with nibolumab for non-small cell lung cancer - Early secondary treatment with nibolumab for NSCLC
Fujita Health University School0 sites30 target enrollmentJanuary 1, 2018
Conditionsnon-small cell lung cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- non-small cell lung cancer
- Sponsor
- Fujita Health University School
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Active auto\-immune disease An inappropriate case judged by doctor in charge
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
?Estudio de fase II de tratamiento neoadyuvante con gemcitabina, Tarceva® y oxaliplatino, seguido de quimiorradioterapia con Tarceva® y gemcitabina en pacientes con adenocarcinoma pancreático de resecabilidad borderline?.PHASE II STUDY OF NEOADYUVANT TREATMENT WITH GEMCITSBINE, TARCEVA AND OXALIPLATIN FOLLOWED BY CHEMORADIOTERAPY WITH TARCEVA AND GEMCITABINE IN PATIENTS WITH PANCREAS ADENOCARCINOMA WITH BORDERLINE RESECABILITY - GEMERLOXAEUCTR2010-021872-27-ESInstitut Català d?Oncologia (ICO)
Completed
Phase 2
Phase 2 trial of first-line combination therapy of cisplatin, pemetrexed and nivolumab in participants with unresectable malignant pleural mesotheliomamalignant pleural mesotheliomaJPRN-UMIN000030892Okayama Rosai Hospital18
Recruiting
Not Applicable
Phase I/II study of Second-lIne therapy of preoperative cheMoradiothERApy with gemcitabine and nab-paclitaxel for locally advanced pancreatic canceR (SIMERAR trial)Patients with locally advanced pancreatic cancer (BR-A or UR-LA) scheduled for pancreatic resectionJPRN-UMIN000046618Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama45
Not yet recruiting
Phase 2
To determine whether the intensification of treatment in the form of chemotherapy and EGFR TKI gefitinib) combination increases survival among a â??high riskâ?? sub population of patients with lung cancer who have an EGFR mutatioHealth Condition 1: C34- Malignant neoplasm of bronchus andlungCTRI/2022/02/040621CMC Vellore
Active, not recruiting
Not Applicable
Phase II trial assessing neoadjuvant therapy with FEC 100 followed by Taxotere® (docetaxel) plus Vectibix® (panitumumab) in patients with operable, HR and Her-2 negative breast cancer. TVA study. - TVA studyRH- and Her2- operable breast cancer, in neoadjuvant situationMedDRA version: 9.1Level: LLTClassification code 10022882Term: Invasive ductal breast cancerEUCTR2009-012853-39-FRCentre Jean Perrin